FDA approves Regeneron's gene therapy for inherited deafness

The U.S. FDA approved Regeneron's gene therapy for a rare genetic form of deafness, marking a positive regulatory milestone for the company. The decision supports Regeneron's biotech pipeline and highlights progress in gene therapy innovation. Market impact is likely company-specific rather than sector-wide.

Analysis

The U.S. FDA approved Regeneron's gene therapy for a rare genetic form of deafness, marking a positive regulatory milestone for the company. The decision supports Regeneron's biotech pipeline and highlights progress in gene therapy innovation. Market impact is likely company-specific rather than sector-wide.